These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 9138083)

  • 1. Altered cell shape is linked to increased p34cdc2 gene expression in fibroblasts expressing a mutant E2F-1 transcription factor.
    Logan TJ; Jordan KL; Evans DL; Hall DJ
    J Cell Biochem; 1997 Apr; 65(1):83-94. PubMed ID: 9138083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of a deletion mutant of the E2F1 transcription factor in fibroblasts lengthens S phase and increases sensitivity to S phase-specific toxins.
    Logan TJ; Evans DL; Mercer WE; Bjornsti MA; Hall DJ
    Cancer Res; 1995 Jul; 55(13):2883-91. PubMed ID: 7540951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in fibronectin expression and alteration in cell morphology are coincident in NIH3T3 cells expressing a mutant E2F1 transcription factor.
    Jordan-Sciutto KL; Logan TJ; Norton PA; Derfoul A; Dodge GR; Hall DJ
    Exp Cell Res; 1997 Nov; 236(2):527-36. PubMed ID: 9367638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mutant E2F-1 transcription factor that affects the phenotype of NIH3T3 fibroblasts inefficiency associates with cyclin A-cdk2.
    Jordan-Sciutto KL; Hall DJ
    Biochem Cell Biol; 1998; 76(1):37-44. PubMed ID: 9666304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase upregulates E2F-1 promoter activity and DNA pol alpha expression during early S phase.
    Simbulan-Rosenthal CM; Rosenthal DS; Luo R; Smulson ME
    Oncogene; 1999 Sep; 18(36):5015-23. PubMed ID: 10490838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F.
    Ohtani K; Iwanaga R; Nakamura M; Ikeda M; Yabuta N; Tsuruga H; Nojima H
    Oncogene; 1999 Apr; 18(14):2299-309. PubMed ID: 10327050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An early S phase checkpoint is regulated by the E2F1 transcription factor.
    Stubbs MC; Strachan GD; Hall DJ
    Biochem Biophys Res Commun; 1999 Apr; 258(1):77-80. PubMed ID: 10222238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
    Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
    Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F.
    Hiyama H; Iavarone A; Reeves SA
    Oncogene; 1998 Mar; 16(12):1513-23. PubMed ID: 9569018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered shape and cell cycle characteristics of fibroblasts expressing the E2F1 transcription factor.
    Logan TJ; Jordan KL; Hall D
    Mol Biol Cell; 1994 Jun; 5(6):667-78. PubMed ID: 7949423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells.
    Davis JN; McCabe MT; Hayward SW; Park JM; Day ML
    Cancer Res; 2005 May; 65(9):3633-42. PubMed ID: 15867358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-myc-enhanced S phase entry in keratinocytes is associated with positive and negative effects on cyclin-dependent kinases.
    Alexandrow MG; Moses HL
    J Cell Biochem; 1998 Sep; 70(4):528-42. PubMed ID: 9712150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription factors of the Sp1 family: interaction with E2F and regulation of the murine thymidine kinase promoter.
    Rotheneder H; Geymayer S; Haidweger E
    J Mol Biol; 1999 Nov; 293(5):1005-15. PubMed ID: 10547281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
    Wang H; Shao N; Ding QM; Cui J; Reddy ES; Rao VN
    Oncogene; 1997 Jul; 15(2):143-57. PubMed ID: 9244350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive expression of the E2F1 transcription factor in fibroblasts alters G0 and S phase transit following serum stimulation.
    Logan TJ; Jordan KL; Hall DJ
    Biochem Cell Biol; 1996; 74(1):21-8. PubMed ID: 9035687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association with E2F-1 governs intracellular trafficking and polyubiquitination of DP-1.
    Magae J; Illenye S; Chang YC; Mitsui Y; Heintz NH
    Oncogene; 1999 Jan; 18(3):593-605. PubMed ID: 9989809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Pur alpha and E2F-1 suppresses transcriptional activity of E2F-1.
    Darbinian N; Gallia GL; Kundu M; Shcherbik N; Tretiakova A; Giordano A; Khalili K
    Oncogene; 1999 Nov; 18(46):6398-402. PubMed ID: 10597240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1.
    Halaban R; Cheng E; Zhang Y; Mandigo CE; Miglarese MR
    Oncogene; 1998 May; 16(19):2489-501. PubMed ID: 9627115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters.
    O'Connor RJ; Schaley JE; Feeney G; Hearing P
    Oncogene; 2001 Apr; 20(15):1882-91. PubMed ID: 11313936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.